Revitope

Revitope is an early-stage biotechnology company dedicated to developing the next generation of T-cell redirecting biologics. Revitope is developing a new class of bio-prodrugs, referred to as Programmable Antibody Circuits (PAC), designed to concentrate immune activation on the surface of cancer cells while expanding antigen targeting space. Utilizing our Precision GATE TM technology platform, we are constructing a series of novel cancer immunotherapies aimed at triggering focused and potent immune responses to eradicate tumor cells while sparing healthy tissues.